EPC by Intracoronary Injection in Patients With Chronic Stable Angina

Coronary Artery Disease Clinical Trial

Official title:

A Study for Testing Safety and Efficacy of the Administration of Blood-Borne Autologous Endothelial Progenitor Cells to Alleviate Anginal Symptoms and Myocardial Ischemia in Patients With Severe Anginal Syndrome

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00384514
• Other study ID #: TV-001
• Status: Active, not recruiting
• Phase: Phase 2
• First received: October 5, 2006
• Last updated: October 19, 2006
• Start date: July 2004
• Est. completion date: September 2006

Study information

• Verified date: October 2006
• Source: TheraVitae Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Thailand: The Ethical Committee on Research Involving Human Subject ,Faculty of Medicine Siriraj Hospital,Mahidol University,Bangkok
• Study type: Interventional

Clinical Trial Summary

Study title:A Study for Testing Safety and Efficacy of the administration of Blood-Borne Autologous Endothelial Progenitor Cells to Alleviate Anginal Symptoms and Myocardial Ischemia in Patients with Severe Anginal Syndrome

Principle Investigator: Assoc. Prof. Damras,Tresukosol,M.D.,Head of Cardiac Catherlization unit,Division of Cardiology,Department of Medicine,Faculty of Medicine Siriraj Hospital,Mahidol University

Study objective : To determine the safety and efficacy of intracoronary injection of blood-borne autologous EPCs in relieving symptoms of angina pectoris in symptomatic patients treated with maximal medical therapy with an occluded coronary artery supplying ischemic myocardium Study Design : Phase II, a single center,a non-randomized,open-label trial,

Study population :

Total expected no. of patients : 24

main selection criteria :

• Patients with chronic stable angina on maximal medical therapy and an occluded coronary artery supplying an ischemic viable myocardial region as shown on Sesta-mibi scan. On coronary angiography,the occluded coronary artery must have a patent proximal segment of at least 30 mm with at least one side branch to enable the injection of the EPC if the vessel remains occluded despite the attempted angioplasty efforts.

• Age 18-80 years

• Ejection fraction >35 % on Sesta-mibi scan

• Sestamibi scan (myocardial perfusion) during exercise or dipyridamole,demonstrating regional reversible ischemia in an area relating to the occluded coronary artery.

Investigational Product : At D-8 250 ml of blood drawn from the patients for production of autologous EPCs or ACPs (VescellTM), On D0 ,at least 1.5 million EPCs with viability >75 % suspended in 6 ml sterile cell culture medium will be injected to the same patients by intracoronary artery.

The study consists of 4 periods:Screening ( D-14to-9&D-8,Treatment(D0),Acute Safety follow-up (D1&D2),Chronic follow-up (D30,D90&D180)period ,total follow-up of each case is 6 months.

Evaluation criteria :

Safety : no.& duration of adverse event & serious adverse event

Efficacy :

• change from baseline to 1,3,6 months of CCS, 6-minute walking test

• change from baseline to 3 & 6 months of Sesta-mibi scan

• change from baseline to 3 & 6 months of symptom-limited exercise time,exercise-induced ischemia & METs on Sesta-mibi scan Duration of study: July 2004-December 2006

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 24
• Est. completion date: September 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with chronic stable angina on maximal medical therapy and an occluded coronary artery supplying an ischemic viable myocardial region as shown on Sestamibi scan. On coronary angiography, the occluded coronary artery must have a patent proximal segment of at least 30 mm with at least one side branch to enable the injection of the EPC if the vessel remains occluded despite the attempted angioplasty efforts.

• Patients are not candidates for or are not willing to undergo CABG surgery.

• Age 18 to 80 years

• Male or non-pregnant, non-lactating female

• Ejection fraction >35% on Sestamibi

• Sestamibi scan (myocardial perfusion) during exercise or dipyridamole, demonstrating regional reversible ischemia in an area relating to the occluded coronary artery.

• Informed consent obtained and consent form signed

Exclusion Criteria:

• Patients not satisfying the coronary angiography and Sestamibi criteria

• Patient who received blood transfusions during the previous 4 weeks (to exclude the potential of non-autologous EPCs in the harvested blood).

• Inability to communicate (that may interfere with the clinical evaluation

• Myocardial infarction during the preceding 3 months

• Significant valvular disease or after valve replacement

• After heart transplantation

• Cardiomyopathy

• Renal failure (creatinine 10% above the upper limit according to the hospital normograms)

• Hepatic failure

• Anemia (lower than 11mg/dl.hemoglobin for female and lower than 12 mg/dl for male)

• Abnormal coagulation tests normal [platelets, PT (INR), PTT]

• Stroke within the preceding 3 years

• Malignancy within the preceding 3 years

• Concurrent chronic or acute infectious disease

• Severe concurrent medical disease (e.g., septicemia, HIV-1,2/HBV/HCV infections, insulin-dependent diabetes mellitus, systemic lupus erythematosus, multiple sclerosis, amyotrophic lateral sclerosis)

• Chronic immunomodulating or cytotoxic drugs treatment

• Patients who have rectal temp. above 38.40C for 2 consecutive days

• Patient unlikely to be available for follow-up

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Angina, Stable
• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Device:
• VesCell (TM)-Autologous EPCs/Angiogenic Cell Precursors

Locations

Country	Name	City	State
Israel	Dr. Valentin Fulga	Kiryat Weizmann Science Park, Nes Zionna

Sponsors (2)

Lead Sponsor	Collaborator
TheraVitae Ltd.	Mahidol University

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety : no.& duration of adverse event & serious adverse event
Primary	Efficacy :change from baseline to 1,3,6 months of CCS, 6-minute walking test
Secondary	Efficacy : change from baseline to 3 & 6 months of Sesta-mibi scan
Secondary	: change from baseline to 3 & 6 months of symptom-limited exercise time,exercise-induced ischemia & METs on Sesta-mibi scan